Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-silymarin for prevention of doxorubicin-cyclophosphamide–induced liver damage in non-metastatic breast cancer
IRCT20200408046990N13Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of silymarin in breast cancer, sponsored by Mashhad University of Medical Sciences. Started Sep 2023; status: completed.
02
Drugs
silymarin
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20200408046990N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200408046990N13.